gatifloxacin has been researched along with Keratitis in 19 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Keratitis: Inflammation of the cornea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A soft and biocompatible hydrogel exhibiting a higher loading and the sustained release of gatifloxacin (GFLX) was developed as the potential matrix to fabricate a therapeutic contact lens for curing bacterial keratitis." | 7.79 | Preparation and characterization of a hydrogel carrier to deliver gatifloxacin and its application as a therapeutic contact lens for bacterial keratitis therapy. ( Fu, Y; Huang, Y; Lu, Q; Lv, H; Ma, D; Shi, Y; Xue, W; Zhong, J, 2013) |
| "The objective of the present study was to evaluate the effectiveness of topically applied gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis in a rabbit model." | 7.78 | Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis. ( Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W, 2012) |
| "In the rabbit keratitis model, the ocular inflammation was significantly reduced by gatifloxacin as compared to levofloxacin but there was no significant difference between the groups in the number of viable bacteria." | 7.74 | Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis. ( Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T, 2008) |
| " A MEDLINE search was conducted using the following search terms: moxifloxacin or gatifloxacin; levofloxacin; minimum inhibitory concentration or prevention or prophylaxis; keratitis or endophthalmitis." | 4.84 | Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. ( Scoper, SV, 2008) |
| "A soft and biocompatible hydrogel exhibiting a higher loading and the sustained release of gatifloxacin (GFLX) was developed as the potential matrix to fabricate a therapeutic contact lens for curing bacterial keratitis." | 3.79 | Preparation and characterization of a hydrogel carrier to deliver gatifloxacin and its application as a therapeutic contact lens for bacterial keratitis therapy. ( Fu, Y; Huang, Y; Lu, Q; Lv, H; Ma, D; Shi, Y; Xue, W; Zhong, J, 2013) |
| "The objective of the present study was to evaluate the effectiveness of topically applied gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis in a rabbit model." | 3.78 | Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis. ( Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W, 2012) |
| "In the rabbit keratitis model, the ocular inflammation was significantly reduced by gatifloxacin as compared to levofloxacin but there was no significant difference between the groups in the number of viable bacteria." | 3.74 | Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis. ( Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T, 2008) |
| "The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin." | 3.72 | Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003) |
| "Cefazolin resistance was seen in 13." | 1.72 | Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers. ( Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T, 2022) |
| " Two modified melittin peptides displayed rapid bactericidal properties against antibiotic-resistant strains, low innate resistance development by pathogenic bacteria, remained nonimmunogenic for T lymphocytes, and increased bioavailability in tear fluids." | 1.56 | Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. ( Agrawal, R; Barathi, VA; Beuerman, RW; Chan, LW; Jie, TY; Koh, SK; Lakshminarayanan, R; Leng, ET; Mayandi, V; Sebastian, TM; Somaraju Chalasani, ML; Ting, DSJ; Urf Turabe Fazil, MH; Varadarajan, J; Verma, NK; Xi, Q; Zhou, L, 2020) |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, S | 1 |
| Koh, JJ | 1 |
| Aung, TT | 1 |
| Sin, WLW | 1 |
| Lim, F | 1 |
| Wang, L | 1 |
| Lakshminarayanan, R | 2 |
| Zhou, L | 2 |
| Tan, DTH | 1 |
| Cao, D | 1 |
| Beuerman, RW | 2 |
| Ren, L | 1 |
| Liu, S | 1 |
| Mayandi, V | 1 |
| Xi, Q | 1 |
| Leng, ET | 1 |
| Koh, SK | 1 |
| Jie, TY | 1 |
| Barathi, VA | 1 |
| Urf Turabe Fazil, MH | 1 |
| Somaraju Chalasani, ML | 1 |
| Varadarajan, J | 1 |
| Ting, DSJ | 1 |
| Chan, LW | 1 |
| Agrawal, R | 1 |
| Sebastian, TM | 1 |
| Verma, NK | 1 |
| Soni, T | 1 |
| Gunasekaran, R | 1 |
| Das, S | 1 |
| Mitra, S | 1 |
| Prajna, NV | 1 |
| Prajna, L | 1 |
| Sharma, S | 1 |
| Mohamed, A | 1 |
| Shi, Y | 1 |
| Lv, H | 1 |
| Fu, Y | 1 |
| Lu, Q | 1 |
| Zhong, J | 1 |
| Ma, D | 1 |
| Huang, Y | 1 |
| Xue, W | 1 |
| Hamilton, C | 1 |
| Seamone, CD | 1 |
| Darvish, M | 1 |
| Gupta, RR | 1 |
| Romanowski, EG | 1 |
| Mah, FS | 1 |
| Kowalski, RP | 1 |
| Yates, KA | 1 |
| Gordon, YJ | 1 |
| Scoper, SV | 1 |
| Callegan, MC | 1 |
| Novosad, BD | 1 |
| Ramadan, RT | 1 |
| Wiskur, B | 1 |
| Moyer, AL | 1 |
| Lekhanont, K | 1 |
| Chuckpaiwong, V | 1 |
| Chongtrakool, P | 1 |
| Aroonroch, R | 1 |
| Vongthongsri, A | 1 |
| Park, JH | 1 |
| Song, NH | 1 |
| Koh, JW | 1 |
| Wu, X | 1 |
| Jiang, H | 1 |
| Xu, Y | 1 |
| Yue, W | 1 |
| Yang, L | 1 |
| Song, Z | 1 |
| Chen, H | 1 |
| Liu, T | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Mittal, V | 1 |
| Fernandes, M | 1 |
| Tungsiripat, T | 1 |
| Sarayba, MA | 2 |
| Kaufman, MB | 1 |
| Sweet, PM | 2 |
| Taban, M | 2 |
| Carpenter, TR | 1 |
| McDonnell, PJ | 2 |
| Shamie, N | 1 |
| Reiser, BJ | 1 |
| Graff, JM | 1 |
| Kesler-Diaz, A | 1 |
| Osann, KE | 1 |
| Donnenfeld, RS | 1 |
| Perry, HD | 1 |
| Solomon, R | 1 |
| Jensen, HG | 1 |
| Stein, J | 1 |
| Snyder, RW | 1 |
| Wittpenn, JR | 1 |
| Donnenfeld, ED | 1 |
| Hamam, RN | 1 |
| Noureddin, B | 1 |
| Salti, HI | 1 |
| Haddad, R | 1 |
| Khoury, JM | 1 |
| de la Cruz, J | 1 |
| Behlau, I | 1 |
| Pineda, R | 1 |
| Wada, T | 1 |
| Kida, T | 1 |
| Inoue, T | 1 |
| Tokushige, H | 1 |
| Naka, H | 1 |
| Sakaki, H | 1 |
2 reviews available for gatifloxacin and Keratitis
| Article | Year |
|---|---|
Multiple parallel-line endotheliitis: case report and literature review of an emerging entity.
Topics: Anti-Bacterial Agents; Corneal Edema; Corneal Stroma; Corneal Topography; Drug Therapy, Combination; | 2016 |
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Endophthalmitis; Fluoroquinolones; Ga | 2008 |
17 other studies available for gatifloxacin and Keratitis
| Article | Year |
|---|---|
Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
Topics: Animals; Anti-Bacterial Agents; Arginine; ATP Binding Cassette Transporter, Subfamily B, Member 1; C | 2017 |
Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Anti-Bacterial Agents; Antifungal Agents; Bac | 2020 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacte | 2022 |
Preparation and characterization of a hydrogel carrier to deliver gatifloxacin and its application as a therapeutic contact lens for bacterial keratitis therapy.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cell Line; Contact Lenses; Drug Carriers; Fluo | 2013 |
Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis.
Topics: Animals; Anti-Bacterial Agents; Benzalkonium Compounds; Corneal Stroma; Disease Models, Animal; Drug | 2008 |
Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Evaluati | 2009 |
Pythium insidiosum keratitis in contact lens wear: a case report.
Topics: Anti-Infective Agents; Contact Lenses, Hydrophilic; Corneal Ulcer; Disposable Equipment; Drug Admini | 2009 |
Achromobacter xylosoxidans keratitis after contact lens usage.
Topics: Achromobacter denitrificans; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Contact Lenses, Ex | 2012 |
Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents, Local; Colony Count, Microbial; Conjunctival Diseases; Cornea; Eye; | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
Cotrimoxazole-resistant Nocardia sclerokeratitis: effective therapy with fourth-generation fluoroquinolones.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Resi | 2012 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mode | 2003 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantat | 2005 |
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cornea; Disease Models, Animal; Eye Infections, Bacte | 2006 |
Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolone.
Topics: Adult; Amikacin; Amputation, Surgical; Anti-Bacterial Agents; Clarithromycin; Corneal Stroma; Debrid | 2006 |
Atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth-generation fluoroquinolone therapy.
Topics: Adult; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacterial; Eye Infections, Bacterial; | 2007 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluor | 2008 |